South Korea’s SK Bioscience and the UK’s GlaxoSmithKline on Tuesday said they would start a phase 3 clinical study of SK’s Covid-19 vaccine candidate combined with GSK’s pandemic vaccine booster
The randomised, active-controlled global trial will enrol around 4,000 participants from a range of countries and will aim to evaluate GBP510’s safety and immunogenicity compared to the AstraZeneca/Oxford University Covid-19 vaccine.
Results from the late-stage study are expected in the first half of 2022 after which the vaccine is expected to be supplied at scale worldwide through the COVAX facility, the two companies said in a statement.
